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The prevalence of integrase strand transfer inhibitor (INSTI)–
transmitted drug resistance (TDR) may increase with the in-
creasing use of INSTIs. We analyzed the prevalence of INSTI
TDR in the Swiss HIV Cohort Study (2008–2014). In 1 of
1316 drug-naive samples (0.1%), a major INSTI TDR mutation
was detected. Prevalence was stable, although INSTIs were in-
creasingly used. We showed that this is in contrast to the intro-
duction of previous drug classes, in which more treatment
failures with resistant strains occurred and TDR was observed
more rapidly. We demonstrated on a population-level that it
is possible to avoid TDR to a new drug class for years.
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Integrase strand transfer inhibitors (INSTIs) are increasingly
prescribed to treat human immunodeficiency virus (HIV)–
infected patients [1].With the increasing use of INSTIs and sub-
sequent treatment failures on INSTIs, the number of transmit-
ted INSTIs resistance is expected to increase, as observed for
other drug classes [2, 3]. The risk of transmission of drug resis-
tance is particularly high in populations where treatment-
experienced patients are not receiving suppressive antiretroviral
treatment (ART) [2].
Despite increasing use of INSTIs, transmission of INSTI re-
sistance has not been widely reported [4, 5]. There are some
anecdotal cases in which the transmission of major INSTI resis-
tance was reported [6, 7]. Minor resistance mutations are most
likely polymorphic and occur more often in non–B subtype
HIV infections, compared with subtype B infections [4, 5].
We aimed to analyze the prevalence of transmitted INSTI re-
sistance in the Swiss HIV Cohort Study (SHCS) and to identify
risk factors for its occurrence. In addition, we intended to spec-
ify the transmission potential for INSTI resistance in the SHCS
population and to set it in historical context.
METHODS
Study Population
We used data from the SHCS and the SHCS drug resistance
database. The SHCS is an ongoing, nationwide, multicenter,
clinic-based observational study [8]. The SHCS is highly repre-
sentative and includes 85% of newly infected patients and at
least 75% of patients receiving antiretroviral treatment in Swit-
zerland [2, 8]. Sequences from genotypic drug resistance tests
(GRTs) are stored in a central database (SmartGene; Integrated
Database Network System, version 3.6.14) [2]. Subtypes were
defined using REGA HIV-1 Subtyping (V3.0; available at:
http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-
hiv/typingtool#). If results were inconclusive, the analysis was
repeated with Comet subtyping (V1.0; available at: http://
comet.retrovirology.lu/). The SHCS has been approved by the
ethical committees of all participating institutions, and written
informed consent has been obtained from all participants [8].
The SHCS drug resistance database contained 1724 GRTs from
theHIV-1 integrase gene, of which 1168 were prospectively and 556
retrospectively sequenced. A total of 1521 of 1724 GRTs were from
INSTI-naive patients, and 1057 of 1724 were from treatment-naive
patients. The retrospective sequencing was done systematically. All
available samples from patients for whom HIV infection was
diagnosed during 2008–2011 were sequenced, as well as baseline
samples from drug-experienced patients who started INSTI-
containing treatment and patients who experienced a treatment
failure on INSTIs.
INSTI Resistance
To estimate the prevalence of transmitted INSTI resistance up
to 2014, we included 1316 patients who had ≥1 GRT performed
for the integrase gene before the first exposure to an INSTI (ear-
liest GRT per patient chosen). Samples retrieved before 2008 were
summarized together as a group. We considered drug resistance mu-
tations listed by the International Antiviral Society–USA in 2015 and
differentiated between minor mutations (T66AK, L74 M, E92G,
T97A, E138AK, G140AS, and R263K) and major mutations (T66I,
E92Q, F121Y, Y143CHR, S147G, Q148HKR, and N155H) [9].
We performed a logistic regression analysis, adjusted for HIV
subtype, to quantify the impact of calendar year on transmitted
INSTI resistance.
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To account for potential reversion of transmitted drug resis-
tance mutations in the absence of drug pressure, we performed
a subanalysis that included only GRTs from recently infected,
treatment-naive patients. A recent infection was defined as fol-
lows (details are described elsewhere [2]): acute HIV-1 infection
described by the physician, documented seroconversion (<1
year between the last negative test result and first positive test
result), or an ambiguity score of ≤0.5% combined with a
CD4+ T-cell count of >200 cells/µL [10].
Transmission Potential of Drug Resistance
To estimate the transmission potential of INSTI resistance and
to put our findings into historical context, we compared differ-
ent aspects of the period after the introduction of INSTI (2008–
2014) to the periods after introduction of nonnucleoside reverse
transcriptase inhibitors (NNRTIs) (1998–2004), unboosted
protease inhibitors (PIs) (1996–2002), and ritonavir-boosted
PIs (PI/r; 1999–2005). We differentiated unboosted PIs and
PI/r because of the better potency of PIs/r. We compared the
number of patients receiving the specific drug classes, the num-
ber of patients with no response to specific drug classes, and the
number of patients detected with ≥1 drug resistance mutation
affecting the specific drug class. Additionally, we compared 3
different types of population viral load (PVL): (1) PVL after
first exposure to the specific drug class (after ≥120 days of con-
tinuous treatment), (2) PVL after treatment failure on a specific
drug class, and (3) PVL after detection of the first major drug
resistance mutation affecting the specific drug. To calculate the
PVL, we summed the log10-transformed viral loads from the re-
spective patients. Each patient contributed to each year once. If
a patient had ≥2 measurements within the same year, we calcu-
lated the mean of the log10-transformed viral load.
Treatment failure was defined as ≥1 viral load of ≥500 HIV-1
RNA copies/mL (after 180 days of continuous treatment or pre-
vious viral suppression) followed by a treatment change or stop.
Statistical analyses were performed with Stata SE, version 14.0
(StataCorp, College Station, Texas).
RESULTS
Transmission of INSTI Resistance Mutations
INSTI resistance mutations were rarely detected among INSTI-
naive patients (Supplementary Appendix 1). Only 1 major mu-
tation was found (1 of 1316 [0.1%]). It was T66I, found in a
sample retrieved in 2001. In 38 of 1316 samples (2.9%), viruses
were found with minor INSTI resistance mutations. The most
common minor mutations were L74 M (17 of 1316 [1.3%])
and T97A (16 of 1316 [1.2%]). Minor mutations were more
common in subtype non-B infections as compared to subtype
B infections (24 of 466 [5.2%] vs 14 of 850 [1.6%]; P < .001,
by the Fisher exact test). The detected minor mutations were
most likely polymorphic. They were already present before (in
4 of 157 samples [2.6%]) the introduction of INSTIs in
Switzerland (28 February 2008). We found no evidence for an
increase in prevalence of minor mutations in the years after the
introduction of INSTIs. The yearly prevalence was 2.4% (95%
confidence interval [CI], .6%–5.9%), 3.8% (95% CI, 1.4%–
8.2%), 2.4% (95% CI, 0.8%–5.4%), 3.6% (95% CI, 1.8%–6.6%),
2.5% (95% CI, 0.8%–5.8%), 1.3% (95% CI, 0.2%–4.7%), and
3.9% (95% CI, 1.5%–8.4%) during 2008–2014. The odds ratio
(OR) per calendar year was 0.98 (95% CI, .8–1.2) when per-
forming a logistic regression adjusted for HIV subtype B versus
non-B subtypes (OR, 3.3; 95% CI, 1.7–6.4; P = .001).
The results were similar when we restricted the analysis to re-
cently infected patients. No major mutation was detected in 303
samples. Minor mutations tended to be more common in sub-
type non-B infections (4 of 92 samples [4.4%]) as compared to
subtype B infections (3 of 211 samples [1.4%]; P = .205).
Potential Reasons for the Low Prevalence of Transmission
The prevalence of transmitted INSTI mutations remained low,
although the number of patients receiving INSTI was increas-
ing, from 259 in 2008 to 2180 in 2014 (Supplementary Appen-
dix 2). The low prevalence may be explained by the low number
of patients who were potential transmitters of INSTI resistance.
Between 2008 and 2014, 85 patients experienced a treatment
failure on ART including INSTIs in the entire SHCS database.
Of these, 56 (61%) changed treatment after a median of 49 days
(interquartile range, 15–167 days) following treatment failure,
and a large proportion of these patients reached viral suppres-
sion (<50 HIV-1 RNA copies/mL) later (42 of 47 patients [89%]
with a measurement).
GRTs were performed in 54 of 85 patients (64%) who expe-
rienced a treatment failure on INSTI treatments. In 26 (48%),
GRTs INSTI mutations were found. The following major muta-
tions were most commonly detected: N155H (in 18 [33%]),
Q148H (in 4 [7%]), Y143C (in 4 [7%]), and Y143R (in 3
[6%]). In addition, 13 GRTs with drug-resistant viruses were
performed on samples from patients who had detectable viral
load while receiving ART containing INSTI but did not fulfill
our criteria for nonresponse to treatment. However, the major-
ity of patients ever detected with a major INSTI resistance mu-
tation were successfully treated (HIV-1 RNA load, <50 copies/
mL) at the last study visit (23 of 40 [58%]), died (4 of 40 [10%]),
or stopped participating in the SHCS (8 of 40 [20%]). Our find-
ings reveal that only a very small number of patients are known
to be potential transmitters of INSTI resistance mutations.
Comparison to the Introduction of Other Drug Classes
The transmission of drug resistance mutations against other drug
classes was higher in the years following introduction [2]. An ex-
planation for the difference is that the number of patients who
did not respond to a treatment containing the other drug class
was higher as compared to the number of patients who did not
respond during INSTI treatments (Supplementary Appendix 2).
As mentioned above, in the first 7 years after the introduction of
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INSTIs, only 85 of 2751 patients receiving INSTIs experienced a
virological failure. In the 7 years after the introduction of un-
boosted PIs, PI/r, and NNRTIs, 18.2 times (1543 of 5923), 5.7
times (482 of 5332), and 7.2 times (609 of 4347) more patients
did not respond to the respective ART. The median PVL after
first exposure to INSTIs, after treatment failure during INSTI re-
ceipt, and after detection of INSTI resistance in the 7 years after
introduction of the first INSTI was much lower, compared with
the median PVL after introduction of other drug classes (Figure 1
and Supplementary Appendix 3 and 4).
DISCUSSION
Seven years after introduction of INSTIs in Switzerland, no
transmission of major INSTI resistance mutations was detected
by our study. The major reason for this unexpected absence of
INSTI transmission is most likely the very low transmission po-
tential in the SHCS. Treatment-naive patients had no transmis-
sion potential of INSTI resistance because of lacking INSTI
resistance mutations, and the number of treatment failures dur-
ing INSTI receipt remained remarkably low. Thus, the PVL of
patients who experienced a virological failure during INSTI re-
ceipt or who carried viruses with INSTI resistance mutations
was very low. To put these findings in a historical context was
even more impressive. The transmission potential of resistance
mutations remained very low after the introduction of INSTI as
compared to the time after introduction of PIs and NNRTIs.
Despite these very encouraging and unexpected findings, the
transmission of INSTI resistance most likely cannot be avoided
in the long run [6, 7]. Boyd et al postulated that it is only a mat-
ter of time until the prevalence of transmitted drug resistance
affecting INSTIs is reaching higher levels. However, we demon-
strated that the transmission of drug resistance affecting a new
class can be minimized. The Swiss setting cannot be compared
to other settings (eg, those with limited access to viral load mon-
itoring or no available second-line and third-line therapies). In
these settings, patients may continue to receive failing regimens
and may accumulate more drug resistance mutations. These pa-
tients have a high transmission potential and might also accu-
mulate secondary mutations. Such strains might be transmitted
and fixed in the population and might lead to major public
health issues in the future [2].
Minor mutations were more frequently seen in non-B sub-
type infections, but they probably do not have an impact on
the treatment outcome, as has been shown for minor PI muta-
tions [11, 12]. The sample size was too small to analyze specific
pattern among non-B subtypes.
To our knowledge, this is the largest study to assess the trans-
mission of INSTI resistance in a highly representative popula-
tion. Owing to the similar history of drug approval and
Figure 1. A–D, Population viral load (PVL) of patients treated with integrase strand transfer inhibitor (INSTIs; A), nonnucleoside reverse transcriptase inhibitors (NNRTIs; B),
unboostsed protease inhibitors (PIs; C), and ritonavir-boosted PI (PI/r; D) in the 7 years after introduction of each drug class. The areas represent the PVL after first exposure to
the specific drug class (light gray) and the PVL after virological failure of the specific drug class (dark gray). Abbreviation: HIV-1, human immunodeficiency virus type 1.
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treatment guidelines, our finding most likely also reflects the sit-
uation in other resource-rich settings.
Our study is limited by the fact that not all patients who ex-
perienced virological failure during INSTI receipt had a GRT
performed. This was partially due to the fact that drugs were
switched at low viral loads, making resistance testing less successful
[13]. Viral load measurements and genotypic drug resistance test-
ing have been routinely integrated in clinical care in Switzerland
since 1997 and 2002, respectively, and therefore the PVL, number
of failures, and number of mutations might be slightly underesti-
mated. But these issues do not alter our conclusions.
To summarize, our study demonstrated that the transmission
potential of drug resistance against a new drug class can be min-
imized in a setting coming very close to the World Health Or-
ganization target 90-90-90 [14, 15]. Nevertheless, it might only
be a matter of time until the prevalence of transmitted drug
resistance affecting INSTI reaches notable levels. Of particular
importance will be to investigate the effect of decreasing mon-
itoring frequency that is proposed and performed in some
countries. This may lead to delayed detection of treatment fail-
ures with subsequent emergence of resistance and a higher PVL
of nonresponding patients. From a global health perspective, it
is important that the transmission potential in other settings
can be minimized in a similar way.
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